Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
SAMDAILY.US - ISSUE OF APRIL 26, 2023 SAM #7820
SOLICITATION NOTICE

A -- VACCINE ADJUVANT DISCOVERY PROGRAM

Notice Date
4/24/2023 11:37:06 AM
 
Notice Type
Solicitation
 
NAICS
541714 — Research and Development in Biotechnology (except Nanobiotechnology)
 
Contracting Office
NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
 
ZIP Code
20892
 
Solicitation Number
BAA-DAIT-75N93022R00022
 
Response Due
5/30/2023 12:00:00 PM
 
Archive Date
06/14/2023
 
Point of Contact
Maribel Miranda, Phone: 2406695139, Tom Bahrami, Phone: 2406695147
 
E-Mail Address
maribel.miranda@nih.gov, bahramit@niaid.nih.gov
(maribel.miranda@nih.gov, bahramit@niaid.nih.gov)
 
Description
The purpose of this BAA is to renew the NIAID Adjuvant Discovery Program that supports the identification and�characterization of novel, effective and safe vaccine adjuvants. The process of discovery new adjuvants through this�program must include each of the following areas of research: (1) Identification of novel adjuvant candidates using�high throughput (HTS) approaches and validation that lead compounds stimulate human cells; (2) determination of the�mechanism of action of select lead compounds, including the identification of the receptor(s) the adjuvant candidates�work through and/or the cellular signaling pathways they activate; (3) optimization of lead adjuvant candidates through�formulation and medicinal chemistry, guided by structure-activity relationship (SAR) studies; and (4) verification of�the efficacy of lead compounds as vaccine adjuvants in vivo in an animal model. Offerors are encouraged, but not�required, to evaluate lead adjuvant candidates in model systems of vulnerable populations (e.g., newborns, elderly�or immunocompromised individuals). Lead adjuvant candidates identified under a contract project may also be tested�with different vaccine platforms, including nucleic acid-based vaccines. Not only the shortterm efficacy, but also the�durability of the immune response induced by the adjuvanted vaccine must be evaluated.
 
Web Link
SAM.gov Permalink
(https://sam.gov/opp/d47fb8e0b4d74364af9a2337bfe9717b/view)
 
Record
SN06659912-F 20230426/230424230112 (samdaily.us)
 
Source
SAM.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.